Grisell Ortiz Lasanta
Internal Medicine · San Juan, PRNPI 1538362918
Payments from drug & device makers
Across 1,686 payments — averaging $3480.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron$1.3M
- AbbVie$767K
- Boehringer Ingelheim International GmbH$620K
- Astrazeneca UK Limited$545K
- GSK$543K
- Madrigal Pharmaceuticals$519K
- plus $1.6M from 21 others
Across 13 payments — averaging $153.28 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$2K
- Novo Nordisk AS$121
- Gilead$67
What the payments were for
- Travel & lodging$3,13571%
- Food & beverage$1,28729%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron | 726 | $1,282,499 |
| AbbVie(2 entities) | 87 | $766,604 |
| Boehringer Ingelheim International GmbH | 161 | $620,004 |
| Astrazeneca UK Limited | 15 | $544,557 |
| GSK | 85 | $543,244 |
| Madrigal Pharmaceuticals | 87 | $518,982 |
| Novartis | 19 | $354,673 |
| E.r. Squibb & Sons, L.L.C. | 9 | $250,879 |
| Gilead | 67 | $161,453 |
| Bausch Health US, LLC | 128 | $158,198 |
| Mallinckrodt Hospital Products Inc. | 21 | $142,861 |
| Genentech, Inc. | 26 | $128,039 |
| Novo Nordisk AS | 187 | $118,731 |
| AstraZeneca | 7 | $99,409 |
| Mallinckrodt Enterprises LLC | 12 | $61,809 |
| Merck | 29 | $61,364 |
| Eli Lilly | 2 | $26,291 |
| Boehringer Ingelheim | 2 | $18,147 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 1 | $6,677 |
| Romark Laboratories, LC | 1 | $3,000 |
| Johnson & Johnson | 6 | $100 |
| Janssen Research & Development, LLC | 1 | $58 |
| Taiho Oncology, Inc. | 3 | $54 |
| Intercept Pharmaceuticals, Inc. | 1 | $41 |
| Sanofi | 1 | $31 |
| Eisai Inc. | 1 | $22 |
| Amgen | 1 | $18 |
How this compares
$5,867,744 in reported general payments places this provider in the 95th percentile of 1,043 internal medicine providers in Puerto Rico.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Omega-3 Acid Ethyl Esters | 32 | $1,057 |
| Pantoprazole Sodium | 19 | $204 |
| Famotidine | 15 | $117 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in San Juan
- Ricardo FernandezSan Juan$480K
- Pedro del Valle de TomasSan Juan$114K
- Norma SalgadoSan Juan$21K
- Victor Gordo GonzalezSan Juan$21K
- Roberto Calderon SantiagoSan Juan$20K
- Natalia Almodovar ArbeloSan Juan$9K
- Jeremy FelicianoSan Juan$8K
- Porfirio Diaz-RodriguezSan Juan$8K
- Rafael Figueroa NavarroSan Juan$6K
- Amilcar Torres FigueroaSan Juan$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.